10x Genomics completed the acquisition of CartaNA for $41m.

10x Genomics, an American biotechnology company, completed the acquisition of CartaNA, a Swedish biotechnology company, for $41m. "Our team has been focused on developing In Situ technologies for a number of years, starting with work at Stockholm University and Karolinska Institute. We are thrilled to join 10x and become a part of their Swedish research center in Stockholm as we continue to build and deliver products for scientists around the globe," Malte Kuhnemund, CartaNA co-founder and EVP of R&D.